CMS Will Detail MedCAC Research Role In Response To Industry Concerns
Executive Summary
CMS will more fully describe how it intends to use its Medicare Evidence Development and Coverage Advisory Committee to set research priorities, CMS Chief Medical Officer Barry M. Straube said at an April 30 MedCAC meeting in Baltimore
You may also be interested in...
Part B Drug Compendia For Off-Label Chemotherapy May Be Updated Annually
CMS will annually solicit public comment on updating the list of compendia used by Medicare Part B contractors in making local coverage determinations for off-label cancer drugs and biologicals, according to a proposed rule scheduled for July 12 publication in the Federal Register
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials